Short answer: during a Pre-Submission (Pre-Sub), the FDA focuses on risk, regulatory pathway logic, and evidence strategy—not technical detail overload.
Many founders assume the best way to impress reviewers at the U.S. Food and Drug Administration is to provide as much technical detail as possible.
Short answer: the FDA expects a Pre-Submission (Pre-Sub) to clarify risk, regulatory pathway, and evidence strategy—not to pre-approve your device.
A Pre-Submission meeting allows companies to ask the U.S. Food and Drug Administration targeted questions about their development plan before investing heavily in studies or submissions.
Short answer: FDA failure is not just a regulatory setback. It is a valuation event.
When a medical device company receives a major deficiency letter, Refuse-to-Accept decision, or pathway escalation from the U.S. Food and Drug Administration, investors do not see a technical issue. They see risk materializing.
And risk directly affects exits.
Short answer: most FDA failures are not created during review. They are created months—or years—earlier during poor planning.
By the time a submission reaches the U.S. Food and Drug Administration, the outcome is often already predictable.
FDA does not “surprise” companies. Companies surprise themselves by discovering too late that their strategy never aligned with regulatory expectations
Short answer: most FDA submission failures follow predictable patterns. They are rarely random. They are rarely mysterious. And they are almost always preventable.
Startups often assume failure happens because the science was weak. In reality, failure usually happens because the regulatory strategy was fragmented, optimistic, or reactive
Short answer: FDA rejection is rarely about bad data. It is usually about answering the wrong question.
Most companies that struggle during FDA review did generate data. They ran studies. They collected results. They invested money.
Direct answer: most medical devices do not fail FDA review because the science is weak. They fail because the strategy was weak.
In many cases, the engineering works. The bench testing looks solid. The prototype performs as expected.
But the submission fails because the development plan was not aligned with how the U.S. Food and Drug Administration evaluates risk, evidence, and benefit
Short answer: investors do not just look at your FDA pathway. They look at how realistic your pathway assumptions are. If your regulatory strategy sounds optimistic, your valuation will be discounted. In medical device investing, the chosen pathway—510(k), De Novo, or PMA—is more than a regulatory decision. It is a signal of timeline stability, capital […]
Short answer: marketing similarity is not the same as regulatory substantial equivalence.
Many founders believe that if their device “looks like” something already on the market, they can file a 510(k). That assumption is one of the most common regulatory mistakes in medical device development.
